Romania - rumensk - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

apl swift services (malta) limited - malta - combinatii (candesartanum cilexetil+hct) - compr. - 32mg/25mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic

Romania - rumensk - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

apl swift services (malta) limited - malta - combinatii (candesartanum cilexetil+hct) - compr. - 8mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic

Den europeiske union - rumensk - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - fibroză chistică - alte produse ale sistemului respirator - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

rotapharm ilaclari limited sirketi - metoclopramidum - soluţie perfuzabilă - 2 mg/ml

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

tulip lab private limited - levofloxacinum - comprimate filmate - 500 mg

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

tulip lab private limited - levofloxacinum - comprimate filmate - 750 mg

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

dr. sertus ilac sanayi ve ticaret limited sirketi - moxifloxacinum - comprimate filmate - 400 mg

Romania - rumensk - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

apl swift services (malta) limited - malta - levofloxacinum - sol. perf. - 5mg/ml - chinolone antibacteriene fluorochinolone

Romania - rumensk - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

apl swift services (malta) limited - malta - moxifloxacinum - compr. film. - 400mg - chinolone antibacteriene fluorochinolone

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

rotapharm ilaclari limited sirketi - ciprofloxacinum - comprimate filmate - 500 mg